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Abstract
The use of continuous antibiotic prophylaxis (CAP) was critical in the evolution of vesicoureteral
reflux (VUR) from a condition in which surgery was the standard of treatment to its becoming a
medically managed condition. The efficacy of antibiotic prophylaxis in the management of VUR has
been challenged in recent years, and significant confusion exists as to its clinical value. This review
summarizes the critical factors in the history, use, and investigation of antibiotic prophylaxis in VUR.
This review provides suggestions for assessing the potential clinical utility of prophylaxis.
History and Background
With the recognition of the relationship between renal
scarring, urinary tract infection (UTI), and VUR, the clinical
use of prophylactic antibiotics emerged in the early 1970s.
This was largely the result of the work of Normand and
Smellie,whohad showna reduction in the incidenceofUTI
in childrenwith VUR onCAP [1]. As a clinical strategy, CAP
offered an alternative to surgical correction of VUR and
became the recommendation of the American Urological
Association (AUA) guideline in 1997 [2]. It is useful to
review the data on CAP to understand its influence on the
guidelines of VUR and UTI evaluation and management,
recognizing its critical role in VUR management.
The original reports by Normand and Smellie were of
patients with long histories of recurrent UTI, many of
whom had renal injury (based on intravenous pyelogram
data in most) and VUR. Use of trimethoprim was seen to
alter the UTI rate significantly in most. Importantly, the
approach of Normand and Smellie to these patients
included rigorous management of voiding dysfunction as
well as using CAP. Interestingly, the UTI rate was different
among those with and without renal scarring, suggesting a
different risk for these different groups [3].
Academic debate centered on whether the medical
approach with CAP or the surgical approach offered a
better long-term outcome in terms of reducing the
incidence of acute infection and renal scarring. Three
large clinical trials evaluated this question and demon-
strated no clear advantage for medical or surgical
treatment [4–6]. With increasing recognition of the
potential importance of VUR, and the assumed need
for early prevention of infection and scarring, more
children were diagnosed with VUR, including those
identified through sibling screening and evaluation of
those with prenatal hydronephrosis [7]. Increasingly
aggressive imaging for the child with UTI emerged, and
the VUR population demographic shifted. Fewer patients
with scars were being identified, and some had never
experienced UTI. To attempt to prevent renal scarring
from the recurrence of UTI, CAP became widely used.
Eventually, concerns regarding the risks of CAP, including
antibiotic resistance and the burden of daily medication,
prompted the consideration of discontinuing antibiotic
before reflux resolution [8,9] or never using antibiotics in
some. Many of these children were reported to have good
outcomes, and the overall value of CAP was called into
question.
Several larger prospective randomized studies demon-
strated no benefit from CAP [10–13]. At the same time,
endoscopic therapy with injectable bulking agents was
evolving as an alternative to open surgery and was being
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offered in place of a trial on CAP [14]. As a result, the
value of CAP in any child with VUR has been called into
question and, with that, the value of identifying VUR.
New guidelines have set stringent criteria for evaluating
VUR with invasive imaging (such as voiding cystoure-
throgram, or VCUG) [15,16]. Clinically, this has created
much confusion for parents, pediatricians, and family
practitioners as well as specialists.
Recent studies of continuous antibiotic
prophylaxis
The principal challenges to the use of CAP in VUR today
include concerns regarding lack of demonstrated efficacy
of CAP in children with VUR, evidence of limited
compliance with medication use when placed on CAP,
and the development of antibiotic-resistant organisms.
Several large, multicenter trials of the efficacy of CAP for
VUR have been published in the last 6 years with varying
outcomes. Table 1 summarizes these studies and high-
lights the differences in entry criteria and population
characteristics. Studies showing no benefit to CAP often
included patients with a single UTI, low grades of VUR,
and very little renal damage (when assessed) and have
relatively short follow-up. Themeans of diagnosingUTI in
some included “bag” specimens, which may have
produced artifactual high rates of apparent UTI. Similarly,
many of the boys included were not circumcised, or
circumcision status was unknown, yet this may contribute
to UTI risk.
The study by Craig and colleagues [17], demonstrated a
significant benefit to antibiotic prophylaxis, although the
effect was considered “small” or “intermediate” by some,
and this study also includes children with and without
VUR (as well as a large number who never underwent
VCUG). In contrast, the Swedish Reflux Trial (SRT)
included children with higher grades of VUR (III and IV),
younger age, and a significant incidence of renal injury
based on dimercaptosuccinic acid (DMSA) scanning. It
also included a “run-in” period where children, who had
been diagnosed before 1 year of age, were maintained on
CAP until age 1 year and who still had VUR on follow-up
VCUG [18,19]. Many children had resolved their VUR by
that visit and may have never had another febrile
infection even if not on CAP. It is also possible that
children were more prone to UTI after having been on
CAP but were randomly assigned to surveillance and
therefore taken off CAP on entry.
The National Institutes of Health (NIH), multicenter
prospective, randomized placebo controlled study
of antibiotic prophylaxis in children, the RIVUR
Study (Randomized Intervention for Children with
Vesico-Ureteral Reflux) [20], explored the question of
the clinical efficacy of prophylaxis in children with VUR
grades 1 to 4 from 2 months to 6 years of age. The 2-year
study focused on recurrent febrile UTI (with strict criteria
[24]) as the primary endpoint and treatment failure and
renal scarring as secondary endpoints. In total, over 300
children were followed in the two arms of active
treatment with daily, low-dose trimethoprim-sulfa-
methoxazole and placebo. At two years, the risk of
recurrent febrile UTI was reduced by half in the treatment
arm with a hazard ratio of 0.50 (95% confidence interval
0.34 to 0.74), indicating a significant benefit. There was
no reduction in new renal scarring, which was at a very
low rate in both groups [20]. The benefit of CAP was
more pronounced in those children with evidence of
bladder dysfunction as well as those who initially
presented with a febrile UTI. One concern about the
results of this study is that the size of treatment effect is
small, reducing the rate of recurrent febrile UTI from
about 25% to 12%. It should be borne in mind that the
study population included relatively few patients with
grade 4 VUR and a low rate of baseline renal
abnormalities. This would suggest a relatively lower
risk of VUR complications as compared with the
population of, for example, the SRT [18].
Moreover, Figure 1 shows the incidence of UTI during
follow-up in these studies whether on CAP or not, as
correlated with the incidence of renal damage at
initiation of the study. There is an apparent relationship
between the presence of baseline renal damage and the
risk of UTI off CAP. This clearly suggests potential
predictors or determinants of the efficacy of CAP that
differs between patients and study populations. Other
likely factors to add to this susceptibility may include
age, grade of VUR, bladder and bowel dysfunction
(BBD), and history of prior UTIs. The benefit of CAP
appears greater when the risk of recurrent UTI is higher,
which is precisely the situation of concern.
The differences in the results of these studies raise
significant questions as to the generalizability of these
conclusions and have created significant confusion. With
careful examination of these studies, however, the
reported variation in results may be understood, and
this variation largely reflects different baseline patient
populations.
Possible reasons to explain the differences
in the data (heterogeneity)
This heterogeneity of study populations indicates that
some patients can be safely managed without CAP but
that others are at risk for acute UTI and renal damage and
should be treated with CAP. This is consistent with both
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the historical data as well as more recent case series of
children being managed safely without CAP.
The results of the SRT and the NIH RIVUR study are not
completely inconsistent with the other studies of VUR and
CAP, although the RIVUR study is both appropriately
powered and controlled, particularly for BBD, whereas
many of the other trials were not. Populations with
differing risks of subsequent febrile UTI and renal injury
will likely have different patterns of response to CAP. In
smaller studies, the apparent size and direction of an effect
may be different.
The clinical issue is really, what characterizes the child at
low risk in contrast to one who should be treated with
CAP? Several factors have emerged as likely predictors,
even if they cannot be precisely quantified.
Risk models
In a large health-care system database evaluation,
Conway and colleagues [25] examined children with
UTI for risk factors of recurrence; age, Caucasian race,
and grade IV or V VUR were identified. The study of
Dias and colleagues [26] lends support to the concept
of risk factors for UTI, although their study assessed
Figure 1. Incidence of UTI correlated with rate of baseline renal damage
Comparison of urinary tract infection (UTI) incidence based on the incidence of renal damage at initiation of the Swedish Reflux Trial [19], the PRIVENT
(Prevention of Recurrent urinary tract Infection in children with Vesicoureteric Reflux and Normal Renal Tracts Trial) Trial [17] (Craig and colleagues),
Pennessi and colleagues [12], Montini and colleagues [11], Garin and colleagues [10], the RIVUR (Randomized Intervention for Children with Vesico-Ureteral
Reflux) Trial [20], and Swerkersson and colleagues (No CAP in patients with grade I-II; CAP in grade III-V) studies.
The size of the circle is proportional to the number of patients in each group. This chart demonstrates that the risk of a cohort of children to develop a
subsequent UTI is correlated with their baseline rate of renal damage. This is not necessarily causal, but the presence of renal injury identifies a group of
children at a statistically higher risk of further UTI and renal injury. It also suggests that various studies have very different elements of baseline risk, yet we
typically lump them together. This type of “ecological plot” shows relationships between clinical factors and outcomes that shed light on what may define a
population’s risk of a particular outcome.
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risk of UTI on CAP and did not attempt to address the
risk of UTI without CAP. Using a model of risk for
recurrent UTI, they identified female gender, dysfunc-
tional voiding (or BBD), and severe VUR as risk factors
for recurrent UTI.
As a component of developing a clinically useful risk
model for determining the need for CAP, evidence of renal
infection may be useful. This can be shown with an acute
DMSA scan at the time of an acute infection. This logic has
beenused in the so-called “top-down” strategy for selecting
patients with febrile UTIs for VCUGbutmay also be useful
as a determinant of the possible value of CAP [27].
Several studies have suggested that procalcitonin may be
a reliable biomarker that predicts renal parenchymal
involvement and high-grade VUR in children with a first
UTI [26,28]. Procalcitonin levels may offer a better guide
to the need for DMSA scans and the decision to use CAP
in VUR when taken into consideration with the clinical
history [29,30].
It should be recognized that with current data, there is no
certain predictor of risk of acute UTI or renal damage,
and even when better data are obtained, it will not likely
be a clear “yes or no” answer, but shades of gray. At the
same time, these observations permit the development
of a clinical approach to children with VUR in whom
medical therapy is considered. The child likely to have
little need for CAP is the one with a low risk of UTI, with
a limited history of infection (or no prior infection),
normal voiding habits, no evidence of renal scarring, and
lower grades of VUR. It is currently unrealistic to ask for a
simple cutoff level of reflux (Figure 2). Clear indicators
for using CAP would be multiple prior UTIs, renal
scarring, dilating reflux (grades III to V), and abnormal
voiding. Added to this must be social factors as well as
parental preferences and attitudes. The parents of a child
who may have originally presented with severe pyelone-
phritis are seldom willing to risk this recurrence. This
must be factored into the longer-term likelihood of
reflux resolution in the at-risk child. The older child with
high-grade VUR may be much less likely to resolve their
VUR and may be best managed with a curative
intervention. The debate regarding endoscopic or surgi-
cal methods cannot be addressed here, but the risk of
reflux recurrence after endoscopic treatment must be a
factor in this balance. The presence of BBD, a strong
reason to use CAP, should prompt aggressive therapy
and avoidance of surgery if possible. Only if recurrent
infections occur while working to improve BBD should
surgery be a strong recommendation. Endoscopic
therapy for VUR in the face of BBD has been shown to
be less effective [31,32].
Alternatives to continuous antibiotic
prophylaxis in vesicoureteral reflux
Intermittent therapy for urinary tract infection and reflux
An alternative to CAP when managing children with VUR
is the use of antibiotics as intermittent therapy, active
surveillance, and rapid treatment of UTI. The intermittent
therapy approach has had limited study and, certainly in
the SRT, was shown to allowmore renal damage than CAP
in that population [21]. Several significant assumptions
underlie using this approach. The first is that any new UTI
will be rapidly recognized and treated. This assumes a clear
clinical presentation with voiding symptoms or fever,
which is not always the case, and is less reliable in younger
patients. Not all children with pyelonephritis have fever,
and they may not have lower tract symptoms. Coulthard
and colleagues [33] published a concerning report that
attempts to assess the ability to identify UTI in an at-risk
population. The assumption is often made that older
children will be able to report symptoms more promptly
and thereby permit treatment, yet the report showed a
greater delay in treatment in the older patients and
development of new renal scars. Symptoms were not
always predictive of UTI or new renal scarring. This
treatment approach also assumes ready access to evalua-
tion and treatment. For some families, this is simply not
feasible, because of geography or social situation.
Stopping continuous antibiotic prophylaxis
As the utility of CAP for VUR was questioned, several
reports of children with VURmanaged without antibiotics
after a period of treatment with prophylaxis were
published. These were all case series, were without
controls, and had limited follow-up [8,9,34–36]. Clinical
follow-up with some imaging assessment, but often only
ultrasound, was used to define outcomes. These were
highly selected patients rather than a broad population.
They were, in essence, self-selected to a large degree in that
they had not had problems with breakthrough UTI or
overt renal injury. Although it is tempting to generalize
these conclusions to all patients with reflux, thismay be an
over-interpretation of the results [37]. The key conclusions
to these studies should really be seen as demonstrating
that some children with VUR can be safely managed
without CAP. Our challenge then becomes developing a
means by which these children can be identified
prospectively.
A further concern when no CAP is administered is what
to do in case of a new febrile illness or symptomatic UTI.
Ideally, every febrile episode should be fully evaluated
for a UTI in children with VUR. Early recognition of a
new UTI episode is essential in order for it to be
appropriately treated and to prevent new renal damage
[33]. This regimen requires a significant commitment
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Figure 2. Patient profiles for risk of urinary tract infection
Management of these children should be specific to their risk profile rather than simply the grade of reflux.
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from the parents as well as from the primary care
provider. It is therefore essential to educate parents and
caregivers, according to their level of health literacy,
regarding the importance of having a high degree of
suspicion to ensure that appropriate action be taken. It is
also important for the physician to recognize whether
such a regimen is appropriate for a particular family,
considering factors such as medical awareness, access to
health care, and lines of communication with family and
caregivers.
Guidelines
Guidelines are often confusing to practitioners who see
them as proscriptive in terms of patient care. Our view is
that they provide a framework, hopefully based on solid
data, within which appropriate patient care can be
defined. Any experienced clinician will recognize that no
two patients are exactly alike, and the importance of
perceiving the relevant differences is critical. Guidelines
should not be an instrument of policy nor an excuse for
turning off one’s brain. Nonetheless, we cannot ignore
the thought and care that have gone into them, and we
recognize their distinctive perspectives and the impact
that can have on their guidance.
American Urological Association guidelines for
vesicoureteral reflux
In recognition of the recent challenges to the utility and
safety of CAP, the 2010 AUA Clinical Guidelines for
managing VUR have included an option of not using
CAP in selected children. The criteria for use of this
approach include children less than 1 year and with
grade I or II VUR, no history of febrile UTI, and no renal
cortical abnormalities. For children over 1 year, no CAP
is an option for those without history of febrile UTI, no
history of BBD, and no renal cortical abnormalities. The
term “option” is recognition that there is no strong
evidence to support one approach over another and that
both would be considered appropriate [31].
National Institute for Health and Care Excellence
guidelines
The National Health Service in the UK, through the
National Institute for Health and Care Excellence, has
published a set of guidelines aimed at the evaluation and
management of the child with a UTI [38]. These
guidelines have several elements in common with the
American Academy of Pediatrics (AAP) UTI guidelines
and focus on stratifying the severity of the infection and
tailoring subsequent evaluation to that stratification. The
severity of illness, age, and prior history of UTIs are the
critical factors in this determination. Only younger
children with evidence of upper tract infection are
recommended to have any initial imaging, and that is
limited to a renal ultrasound. VCUG is recommended
only in children under 6 months with an atypical UTI,
which includes findings of sepsis, mass, elevated
creatinine, poor urine flow, or failure to respond to
appropriate antibiotics within 48 hours, recurrent UTI, or
non-Escherichia coli infection. DMSA is recommended to
assess the renal parenchyma prior to a VCUG in many
situations with older children. These guidelines are
reasonable in many ways, but it must be recognized
that a certain number of children will have preventable
febrile UTIs and renal scarring. The magnitude of that
number, its clinical impact, and effect on the child are
undefined. It is also uncertain whether this level of
missed prevention is acceptable.
Response to the guidelines has shown reduction in the
number of VCUGs; however, the use of DMSA has
increased [39]. Several studies have shown a significant
rate of patients with missed dilating and high-grade VUR,
many of whom were referred to surgery [40,41]. As
before, the critical determination is to define an
acceptable level of safety in terms of balancing costs,
radiation, and invasiveness with the potential value to
protect children against recurrent UTI. With the value of
prophylactic antibiotics in the setting of VUR being
demonstrated with the RIVUR trial, this balance may fall
more in favor of diagnosing VUR more aggressively.
American Academy of Pediatrics guidelines for diagnosis
and management of febrile urinary tract infection in
infants under 2 years of age
The AAP subcommittee on UTI recently published new
guidelines for the diagnosis and evaluation of febrile UTI
in children less than 2 years of age [16]. Although several
important clarifications in regard to appropriate diag-
nosis and therapy for UTI have been included, a major
change has been the action statement that a routine
VCUG is no longer recommended after an initial febrile
UTI if a renal ultrasound is normal. This conclusion was
based on a meta-analysis of the several studies discussed
above that could not prove a benefit to using CAP for
patients with VUR. As a result, the committee felt that
making the diagnosis of VUR was not justified if CAP was
not an effective therapy. They also cited reports that renal
scarring could occur in the absence of VUR. This
represents a recommendation for significant change in
managing children with febrile UTI, and the implications
remain undefined.
Based on the discussion above, several concerns can be
raised, including the validity of generalizing the results
from these studies to all patients and more specifically to
those under the age of 2. The risk of further renal injury
has been documented with subsequent UTIs, and the
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recommendation of the AAP assumes rapid treatment,
which may not always be the case. This concern may be
more important in underserved communities as also
noted above. Formal responses to the AAP Guideline
have been published and this issue continues to be
debated [42,43]. The impact of the new data from the
RIVUR Study remains to be determined. At present, it
seems prudent to individualize decisions regarding
evaluation of children with febrile UTIs until more
specific indicators of risk are available.
Research
The areas in which we need to focus our research efforts
and resources fall into three categories. One is biomar-
kers of both upper tract infectious injury as well as
susceptibility. It is clear that not all children with
pyelonephritis will develop a scar, but it is not at all
clear why one child will and another will not. Is this a
trait we could identify to guide risk assessment? A second
area is in creating tools for the better clinical assessment
of children with infections, particularly in the arena of
bladder and bowel function and dysfunction. These are
well-recognized key factors, yet we are very poor at
assessing their clinical impact. A third important area is
to define globally acceptable levels of risk prevention.
What is an acceptable number of children to be missed in
terms of their reflux? Although 5% has been a traditional
number, if that is your child who is injured because of
less aggressive investigation or too aggressive an inves-
tigation, the 5% number is hardly a comfort. A common
vocabulary for risk and risk perception needs to be
developed and used in these discussions and guidelines.
Summary
Antibiotic prophylaxis has been shown to be effective in
preventing UTI in some children with VUR but is not
required for all. Although strict criteria for the identifica-
tion of those who are best managed with CAP have yet to
be defined, there is evidence to guide us today. Children
with a clear history of recurrent UTI should be offered
CAP and monitoring. If they continue to have break-
through UTI, alternative approaches, such as surgical
intervention, need to be considered. The child with
documented renal abnormalities on US or DMSA
scanning should be offered CAP as they have shown a
higher risk of further injury and they have less renal
reserve. The child with abnormal voiding patterns or
BBD should be offered CAP while an attempt is made to
correct his or her voiding patterns. Although most BBD is
evident after toilet training, careful questioning of
parents may reveal voiding abnormalities in the infant
as well. Parental understanding of the risks of renal
injury from infection must be clear. If CAP is to be used,
the obligation of education is equally strong in that
failure to follow the medication program may lead to a
false sense of security among both parents and care-
givers. The precision of these criteria is obviously limited,
but they can serve as a means by which clinical decisions
may be made and revised. As the child grows, if VUR
persists, the option of discontinuing CAP becomes more
attractive, and the information regarding the patient’s
risk of UTI improves, based on their clinical patterns.
It is very clear that management of VUR cannot be based
simply on VUR grade or broad statements of the utility of
CAP, but must be individualized. The basis for CAP rests
in the clinical experience from four decades ago, when
many more children suffered from acute febrile UTI and
developed significant renal injury. Therefore, it is
prudent to consider UTIs not only as acute episodes of
illness but also as a first step to possible renal damage. In
carefully conducted studies, its utility in preventing UTI
has been demonstrated.
These data should not be interpreted to indicate that all
children with VUR must be treated with CAP, just as it is
not supported that no child with VUR should be treated
with CAP. All of the recent data examining the role of
CAP point broadly in the direction that we need to
identify subsets of children with differential risk for VUR
complications of recurrent febrile UTI and renal injury.
Although it is not possible to define these risk groups with
a formula, more robust data should ultimately permit
increasingly precise risk stratification and selective
therapy.
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